US clears Pfizer’s biosimilar or Epogen, Procrit
The US Food and Drug Administration has approved Pfizer’s Retacrit, a biosimilar of Amgen’s Epogen and Johnson & Johnson’s Procrit.
Read More
Tag: epoetin alfa
Pfizer’s Epogen/Procrit biosimilar wins US backing
Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
